HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 294 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Young Mom Gives Birth To Healthy Baby Boy In The Midst... June 26, 2020 Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With... July 20, 2021 ESMO Immuno-Oncology Congress 2021, Geneva, Switzerland, 8-11 December November 26, 2021 Struggling Waitress Who Can’t Feed Her 4 Kids After Husband’s Cancer... May 7, 2019 Load more HOT NEWS Single-Fraction SABR Preferred from Resource and Patient Perspectives for Pulmonary Oligometastases The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr.... Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... 2-Year-Old Cancer Survivor With Down Syndrome Hears For First Time: ‘Her...
